GemOx
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma. When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R. The [R]-GemOx regimen consists of: # Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells; # Gemcitabine - an antimetabolite; # Oxaliplatin - a platinum-based alkylating antineoplastic agent.
GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma. When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R. The [R]-GemOx regimen consists of: Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells; Gemcitabine - an antimetabolite; Oxaliplatin - a platinum-based alkylating antineoplastic agent.
Dosing regimen
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1294953028 under CC BY-SA 4.0; modifications have been made.